Zymeworks Gains $250 Mln Payday On FDA Approval For Ziihera In GEA Cancers; Stock Down

Zymeworks (ZYME) received FDA approval for Ziihera in two combination regimens for HER2+ gastroesophageal adenocarcinoma, a clear positive clinical/regulatory milestone. The approval supports a potential expansion of treatment use-cases and commercial opportunity for the program currently licensed to Jazz. Overall, this is likely to be viewed favorably by investors given the FDA-backed label expansion.